The Technical Analyst
Lyra Therapeutics Inc [LYRA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Lyra Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.00% $5.21
America/New_York / 23 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 311.26 mill |
| EPS: | -1.260 |
| P/E: | -4.13 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 59.74 mill |
| Avg Daily Volume: | 0.346 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.13 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.70x |
| Company: PE -4.13 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-1.554 (-129.83%) $-6.76 |
| Date: 2024-04-23 |
| Expected Trading Range (DAY) |
|---|
|
$ 4.74 - 5.68 ( +/- 9.02%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Waksal Harlan | Buy | 275 000 | Common Stock |
| 2024-03-18 | Palasis Maria | Buy | 500 000 | Stock Option |
| 2024-01-30 | Bishop John E | Buy | 200 000 | Stock Options |
| 2024-01-30 | Nieman Richard | Buy | 200 000 | Stock Options |
| 2024-01-30 | Cavalier Jason | Buy | 200 000 | Stock Options |
| INSIDER POWER |
|---|
| 100.00 |
| Last 92 transactions |
| Buy: 35 062 945 | Sell: 0 |
Forecast:
16:00 - $5.21
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $5.21
Forecast 2: 16:00 - $5.21
Forecast 3: 16:00 - $5.21
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.21 (0.00% ) |
| Volume | 0.229 mill |
| Avg. Vol. | 0.346 mill |
| % of Avg. Vol | 66.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LYRA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:31 | sell | $4.83 | N/A | Active |
|---|
LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Latest Press Releases
2024-03-21 16:01:00 - Press Release
Lyra Therapeutics Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
-- data from enlighten i pivotal phase 3 trial of lyr-210 in chronic rhinosinusitis (crs) anticipated q2 2024 -- watertown, mass., march 21, 2024 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (crs), today reported its financial results for the fourth quarter and full year ended december 31, 2023 and provided a corporate update.
2024-03-01 16:01:00 - Press Release
Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Watertown, mass., march 01, 2024 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (crs), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with lyra. the employment inducement awards were approved by lyra's independent directors serving on its compensation committee and granted under the company's 2022 inducement award plan, as amended, and related form of stock option agreement in accordance with nasdaq listing rule 5635(c)(4).
2023-11-07 16:01:00 - Press Release
Lyra Therapeutics Reports Third Quarter 2023 Financial Results And Provides Corporate Update
– additional phase 2 beacon trial ct scan data demonstrated statistically significant improvement in sinus opacification with lyr-220 and provided radiological evidence of improvement in chronic rhinosinusitis (crs) patients who have had prior ethmoid sinus surgery –
2023-11-07 07:00:00 - Press Release
Lyra Therapeutics To Participate In Upcoming Investor Conferences
Watertown, mass., nov. 07, 2023 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (crs), today announced that maria palasis, ph.d., president and chief executive officer, will participate in the following investor conferences in november:
2023-10-16 07:00:00 - Press Release
Lyra Therapeutics Announces Appointment Of Ronan O'brien As Chief Legal Officer
Watertown, mass., oct. 16, 2023 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra) (“lyra” or the “company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (“crs”), today announced the appointment of ronan o'brien, as chief legal officer, effective october 16, 2023.
Latest News
2024-03-28 08:11:05 - Zacks Investment Research
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
Lyra Therapeutics (LYRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
2024-03-25 09:51:22 - Zacks Investment Research
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
Lyra Therapeutics (LYRA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2024-03-22 10:55:18 - Zacks Investment Research
Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High?
The consensus price target hints at a 101.8% upside potential for Lyra Therapeutics (LYRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-08 09:51:08 - Zacks Investment Research
Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going
Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2024-02-29 09:56:09 - Zacks Investment Research
5 Small Drug Stocks to Buy From a Rebounding Industry
Innovation is expected to continue to drive growth of the Medical-Drugs industry. UTHR, ESPR, HRTX, LYRA and ALDX may prove to be good additions to one's portfolio.
2024-02-26 05:02:04 - Zacks Investment Research
Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength?
Lyra Therapeutics, Inc. (LYRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-01-17 10:32:32 - Zacks Investment Research
What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'
Lyra Therapeutics, Inc. (LYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2023-12-20 09:46:04 - Zacks Investment Research
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year to date and have room for more growth in 2024.
2023-12-11 12:02:11 - Zacks Investment Research
5 Small Drug Stocks to Buy on Hopes of Better Prospects in the New Year
Innovation is expected to continue driving growth in the Medical-Drugs industry. DERM, LYRA, AUPH, ALPN and HARP may prove to be good additions to one's portfolio.
2023-10-10 10:56:41 - Seeking Alpha
Lyra Therapeutics: Hold For Phase 3 Topline
Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show promising efficacy data, with LYR-210 in phase 3 trials and LYR-220 in phase 2 trials. Lyra has a market cap of $190mn and enough cash to sustain operations until 2025, but more cash would be desirable.